OTCMKTS:LBTSF Almirall (LBTSF) Stock Price, News & Analysis $13.36 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Almirall Stock (OTCMKTS:LBTSF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Almirall alerts:Sign Up Key Stats Today's Range$13.36▼$13.3650-Day Range$13.36▼$13.3652-Week Range$9.01▼$13.36VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Almirall is a research-driven pharmaceutical company headquartered in Barcelona, Spain. Founded in 1943, the firm has evolved into a specialist in dermatology, dedicating its efforts to understanding and treating a range of inflammatory and chronic skin conditions. Over the decades, Almirall has built a reputation for its targeted R&D approach and its commitment to improving patient outcomes in dermatological care. The company’s core activities span the research, development, manufacturing and marketing of prescription therapies for skin diseases. Its marketed portfolio includes products such as Actikerall, a topical treatment for actinic keratosis; Solaraze, a diclofenac-based gel for actinic keratosis and superficial basal cell carcinoma; and Skilarence (apremilast), an oral therapy for plaque psoriasis. Almirall’s pipeline features investigational small molecules and biologics aimed at conditions like eczema, hidradenitis suppurativa and other inflammatory dermatoses. Almirall operates across Europe, North America and Latin America, leveraging a network of subsidiaries, local partnerships and strategic alliances to distribute its products. The company maintains research centres in Barcelona and other European locations, collaborating with academic institutions and biotech firms to accelerate innovation. Looking ahead, Almirall continues to pursue growth in its core dermatology franchise while exploring adjacent opportunities through licensing deals and co-development agreements.AI Generated. May Contain Errors. Read More Receive LBTSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Almirall and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LBTSF Stock News Headlines3 Global Stocks Estimated To Be Trading Below Fair Value In May 2025May 22, 2025 | finance.yahoo.comAlmiralll, S.A. (LBTSF) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 14 at 2:00 AM | Porter & Company (Ad)Almirall Q1 profit, sales beat forecasts; guidance held on drug momentumMay 12, 2025 | investing.comAlmirall Q1 2025 ResultsMay 12, 2025 | finance.yahoo.comAlmirall Technology Operations Company Profile 2025 - Insights of Digital Transformation Strategies and Innovation ProgramsMarch 31, 2025 | finance.yahoo.comJefferies Keeps Their Buy Rating on Almirall (0O9B)March 12, 2025 | markets.businessinsider.comKepler Capital Reaffirms Their Buy Rating on Almirall (0O9B)February 26, 2025 | markets.businessinsider.comSee More Headlines LBTSF Stock Analysis - Frequently Asked Questions How have LBTSF shares performed this year? Almirall's stock was trading at $9.1730 at the beginning of the year. Since then, LBTSF shares have increased by 45.6% and is now trading at $13.36. How do I buy shares of Almirall? Shares of LBTSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/14/2025Next Earnings (Estimated)11/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:LBTSF CIKN/A Webwww.almirall.com Phone34 93 291 30 00FaxN/AEmployees1,996Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (OTCMKTS:LBTSF) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Almirall, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Almirall With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.